1991
myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens.
Brennan J, O'Connor T, Makuch R, Simmons A, Russell E, Linnoila R, Phelps R, Gazdar A, Ihde D, Johnson B. myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. Cancer Research 1991, 51: 1708-12. PMID: 1847842.Peer-Reviewed Original ResearchConceptsMyc family DNA amplificationSmall cell lung cancerCell lung cancerLung cancerTumor cell linesExtensive-stage small-cell lung cancer patientsSmall cell lung cancer patientsCell linesPatient specimensCell lung cancer patientsDNA copy numberDifferent combination chemotherapyEtoposide/cisplatinDifferent chemotherapy regimensInitiation of therapyLung cancer patientsFrequency of amplificationChemotherapy regimensUntreated patientsCombination chemotherapyCancer patientsSame patientPatientsClinical situationsDNA amplification
1987
Evaluation of circulating malignant cells provides prognostic information in cutaneous T cell lymphoma.
Schechter G, Sausville E, Fischmann A, Soehnlen F, Eddy J, Matthews M, Gazdar A, Guccion J, Munson D, Makuch R. Evaluation of circulating malignant cells provides prognostic information in cutaneous T cell lymphoma. Blood 1987, 69: 841-9. PMID: 3493044, DOI: 10.1182/blood.v69.3.841.bloodjournal693841.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaBlood involvementLymphocyte morphologyRisk factorsCell lymphomaCTCL cellsIndependent risk factorExtent of diseasePretreatment risk factorsPeripheral blood lymphocyte morphologyUntreated patientsVisceral diseaseWorse survivalLymph nodesInitial diagnosisT stageAggressive featuresSkin stageCutaneous tumorsSkin plaquesPrognostic informationPatientsMalignant cellsMultivariate analysisEvaluation of Circulating Malignant Cells Provides Prognostic Information in Cutaneous T Cell Lymphoma
Schechter G, Sausville E, Fischmann A, Soehnlen F, Eddy J, Matthews M, Gazdar A, Guccion J, Munson D, Makuch R, Bunn P. Evaluation of Circulating Malignant Cells Provides Prognostic Information in Cutaneous T Cell Lymphoma. Blood 1987, 69: 841-849. DOI: 10.1182/blood.v69.3.841.841.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaT-cell lymphomaBlood involvementLymphocyte morphologyRisk factorsCell lymphomaCTCL cellsIndependent risk factorExtent of diseasePretreatment risk factorsPeripheral blood lymphocyte morphologyUntreated patientsVisceral diseaseWorse survivalLymph nodesInitial diagnosisT stageAggressive featuresSkin stageCutaneous tumorsSkin plaquesPrognostic informationPatientsMalignant cellsMultivariate analysis
1986
A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate.
Seifter E, Bunn P, Cohen M, Makuch R, Dunnick N, Javadpour N, Bensimon H, Eddy J, Minna J, Ihde D. A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate. Journal Of Clinical Oncology 1986, 4: 1365-73. PMID: 2943877, DOI: 10.1200/jco.1986.4.9.1365.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCisplatinClinical Trials as TopicCyclophosphamideDiethylstilbestrolDoxorubicinDrug Therapy, CombinationHumansMaleMedroxyprogesteroneMedroxyprogesterone AcetateMiddle AgedNeoplasm MetastasisOrchiectomyPilot ProjectsProstatic NeoplasmsConceptsHormonal therapyCombination chemotherapyStable diseasePartial responseHormonal manipulationResponse rateInitial hormonal therapySubsequent hormonal manipulationUntreated metastatic carcinomaObjective response rateIntensive combination chemotherapyNormal testosterone levelsMetastatic prostate cancerEfficacy of chemotherapyProgression of diseaseTime of deathSimilar chemotherapyEndocrine treatmentUntreated patientsObjective responseOverall survivalMetastatic carcinomaModest efficacySerum testosteroneProstate cancer
1984
Predictive factors for tumor response to preoperative chemotherapy in patients with head and neck squamous carcinoma: The head and neck contracts program
Wolf G, Makuch R, Baker S. Predictive factors for tumor response to preoperative chemotherapy in patients with head and neck squamous carcinoma: The head and neck contracts program. Cancer 1984, 54: 2869-2877. PMID: 6208993, DOI: 10.1002/1097-0142(19841215)54:12<2869::aid-cncr2820541210>3.0.co;2-n.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaTumor responsePartial responsePreoperative chemotherapyComplete responseResponse rateTumor characteristicsCell carcinomaHigh tumor response ratesNeck squamous cell carcinomaNodal response ratesResectable stage IIIPatient performance statusPrimary tumor responseTumor response rateNational Cancer Institute trialsNeck squamous carcinomaVariety of patientsLarynx/Preoperative cisplatinChemotherapy regimenIntensive chemotherapyUntreated patientsAdvanced headPerformance statusElevated serum creatine kinase BB levels in patients with small cell lung cancer.
Carney D, Zweig M, Ihde D, Cohen M, Makuch R, Gazdar A. Elevated serum creatine kinase BB levels in patients with small cell lung cancer. Cancer Research 1984, 44: 5399-403. PMID: 6091876.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerSerum CK-BBSerum CK-BB levelsCK-BB levelsCell lung cancerMetastatic sitesLung cancerCK-BBCreatine kinase BB levelsExtensive-stage diseaseSCLC cell linesClinical tumor specimensLimited diseaseClinical responseExtensive diseaseMetastatic diseaseUntreated patientsPretreatment stagingTumor disseminationTumor specimensPatientsBB isoenzymeBb levelsSignificant associationCreatine kinaseSecond malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience.
Tester W, Kinsella T, Waller B, Makuch R, Kelley P, Glatstein E, DeVita V. Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. Journal Of Clinical Oncology 1984, 2: 762-9. PMID: 6547479, DOI: 10.1200/jco.1984.2.7.762.Peer-Reviewed Original ResearchConceptsSecond malignant neoplasmsHodgkin's diseaseMalignant neoplasmsSolid tumorsNational Cancer Institute ExperienceChronic myeloid leukemiaCases of sarcomaRisk of leukemiaUntreated patientsPatient ageHodgkin's lymphomaMedical recordsInstitute experienceMyeloid leukemiaSimilar riskAge 40Treatment groupsPatientsGreater riskLeukemiaTen yearsDiseaseTumorsLymphomaPositive association
1983
Treatment of extensive stage small cell bronchogenic carcinoma Effects of variation in intensity of induction chemotherapy
Brower M, Ihde D, Johnston-Early A, Bunn P, Cohen M, Carney D, Makuch R, Matthews M, Radice P, Minna J. Treatment of extensive stage small cell bronchogenic carcinoma Effects of variation in intensity of induction chemotherapy. The American Journal Of Medicine 1983, 75: 993-1000. PMID: 6316784, DOI: 10.1016/0002-9343(83)90880-x.Peer-Reviewed Original ResearchConceptsHigh-intensity groupSmall cell bronchogenic carcinomaHigh-intensity therapyCell bronchogenic carcinomaInduction chemotherapyInduction courseInduction deathBronchogenic carcinomaDay 1Reversible congestive heart failureModerate-intensity therapyOverall median survivalCongestive heart failureSevere peripheral neuropathyModerate-intensity groupEvaluable patientsComplete remissionInduction therapyInfectious complicationsPartial remissionMedian survivalUntreated patientsComplete responseHeart failurePeripheral neuropathy
1981
Prognostic Implications of Stage of Disease and Sites of Metastases in Patients with Small Cell Carcinoma of the Lung Treated with Intensive Combination Chemotherapy1,2
Ihde D, Makuch R, Carney D, Bunn P, Cohen M, Matthews M, Minna J. Prognostic Implications of Stage of Disease and Sites of Metastases in Patients with Small Cell Carcinoma of the Lung Treated with Intensive Combination Chemotherapy1,2. American Journal Of Respiratory And Critical Care Medicine 1981, 123: 500-7. PMID: 6263137, DOI: 10.1164/arrd.1981.123.5.500.Peer-Reviewed Original ResearchConceptsSmall cell carcinomaExtensive diseaseCentral nervous systemLimited diseaseCell carcinomaBone marrowNervous systemIntensive induction chemotherapyInvolvement of boneSite of metastasisSoft tissueRadionuclide boneAggressive chemotherapyInduction chemotherapyChest roentgenogramMetastatic diseaseUntreated patientsLiver biopsyStaging procedureDistant metastasisFiberoptic bronchoscopyOpposite lungPrognostic implicationsPhysical examinationPretreatment staging
1979
Serum glycoproteins and immunoglobulins in nasopharyngeal carcinoma Correlations with Epstein-Barr virus associated antibodies and clinical tumor stage
Baskies A, Chretien P, Yang C, Wolf G, Makuch R, Tu S, Hsu M, Lynn T, Yang H, Weiss J, Spiegel H. Serum glycoproteins and immunoglobulins in nasopharyngeal carcinoma Correlations with Epstein-Barr virus associated antibodies and clinical tumor stage. The American Journal Of Surgery 1979, 138: 478-488. PMID: 225960, DOI: 10.1016/0002-9610(79)90406-9.Peer-Reviewed Original ResearchConceptsClinical tumor stageElevated antibody titersEpstein-Barr virusSerum levelsAntibody titersTumor stageAcute phase proteinsNasopharyngeal carcinomaTumor presenceImmunoglobulin levelsNormal subjectsEBV antibody titersSerum haptoglobin levelsNeck squamous carcinomaHealthy normal subjectsMonitoring of responseSerum glycoproteinsAnti-EBVUntreated patientsIgA antibodiesEarly antigenSquamous carcinomaStaging systemImmunoglobulins IgAHaptoglobin levelsSerum glycoproteins in head and neck squamous carcinoma Correlations with tumor extent, clinical tumor stage, and T-cell levels during chemotherapy
Wolf G, Chretien P, Elias E, Makuch R, Baskies A, Spiegel H, Weiss J. Serum glycoproteins in head and neck squamous carcinoma Correlations with tumor extent, clinical tumor stage, and T-cell levels during chemotherapy. The American Journal Of Surgery 1979, 138: 489-500. PMID: 90464, DOI: 10.1016/0002-9610(79)90407-0.Peer-Reviewed Original ResearchConceptsΑ1-acid glycoprotein levelsT cell levelsTumor stageAcute phase proteinsUntreated patientsSerum levelsTumor extentCellular immunityImmune reactivitySquamous carcinomaPhase proteinsGlycoprotein levelsSpecific acute phase proteinsCompletion of chemotherapyClinical tumor stageChronic cigarette smokersΑ1-antitrypsin levelsΑ1-antitrypsinCellular immune parametersNeck squamous carcinomaPreoperative chemotherapyRecurrent carcinomaAlbumin levelsControl patientsRegional metastases